Enhanced response to dabrafenib plus trametinib in a patient with BRAFV600E lung cancer harboring an RNF43 variant of unknown significance: a case report

BackgroundLiterature evidence reports that RNF43 (ring finger protein 43) gene mutations could serve as predictive biomarkers of response to certain anti-cancer therapies. To delve deeper into the specific role of RNF43 mutations in lung cancer and their relevance to therapy response, we provide the...

Full description

Saved in:

Bibliographic Details
Main Authors:	Ettore D’Argento, Antonio Vitale, Jacopo Russo, Angelo Minucci, Alessandra Cancellieri, Alessio Stefani, Federico Monaca, Guido Horn, Denis Occhipinti, Paola Troisi, Alessandro Scala, Sara Polidori, Francesco D’Argento, Mariantonietta Di Salvatore, Emilio Bria, Giampaolo Tortora
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2025-07-01
Series:	Frontiers in Oncology
Subjects:	non-small-cell lung cancer dabrafenib trametinib BRAF V600E RNF4 case report
Online Access:	https://www.frontiersin.org/articles/10.3389/fonc.2025.1600457/full
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!

Enhanced response to dabrafenib plus trametinib in a patient with BRAFV600E lung cancer harboring an RNF43 variant of unknown significance: a case report

Similar Items